Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambr Nutri Sci Regulatory News (CNSL)

Share Price Information for Cambr Nutri Sci (CNSL)

Share Price is delayed by 15 minutes
Get Live Data
1.85    0.00 (0.00%)
Bid:
1.70
Ask:
2.00
Spread: 0.30 (17.647%)
Market Cap: £4.40m
CNSL Live PriceLast checked at - London Stock Exchange

Intraday Cambr Nutri Sci Share Chart

Scientific Educational Programme expanded

4 Dec 2023 07:00

RNS Number : 4602V
Cambridge Nutritional Sciences PLC
04 December 2023
 

 

CAMBRIDGE NUTRITIONAL SCIENCES PLC

("CNS" or the "Company" or the "Group")

 

CNS continues to expand Scientific Educational Programme and build relationships at leading Industry Events

 

· Company delivers latest webinar tackling the role of inflammation in irritable bowel syndrome

· Lecture presented in Dubai alongside one of India's key opinion leaders on food sensitivity

· CNS continues to raise its profile at key industry events, helping drive demand for products

 

 

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces developments in its scientific education programme, a key initiative which enables the Company to collaborate with a number of global and UK-based key opinion leaders in the nutritional science field. CNS also highlights the industry events attended recently as it continues its drive to build relationships with healthcare practitioners as well as existing and prospective business partners.

 

Latest Educational Webinar Released: "Inflammation in irritable bowel syndrome: myth or new treatment target"

· Thought-leading topic exploring how food IgG antibodies can activate mast cells in the gut leading to irritable bowel syndrome symptoms.

· In October, CNS's Scientific Director, Dr Nigel Abraham, presented this lecture in person at the International Symposium for food intolerance and Digestive Health ('FIDHC') in Dubai, alongside Mumbai based Dietician and founder of FREEDOM Lifestyle and Wellness Centre, nutrition advisor to the Indian Navy and key opinion leader on food sensitivity testing in India, Dr Naaznin Husein.

 

CNS Raises Awareness with Practitioners Through Networking at Leading UK Industry Conferences

Key to CNS's strategy of maintaining a leadership position is building awareness with healthcare practitioners. These events give the company the opportunity to meet and re-engage with practitioner customers as well as those who are new to food sensitivity testing or taking their first steps in clinical practice.

 

IHCAN 2023 Summit

· CNS's UK team participated in both the November and June IHCAN 2023 summits, the UK's largest integrative health conference and expo held in London.

· Key industry event, attended by approximately 300 integrative health practitioners and guest speakers from around the world.

· Opportunity to explain the clinical utility for the Company's products to future practitioners in the end stages of their training.

· Platform to educate those interested in learning about how embedding food sensitivity testing in their practice can help resolve gut related health issues and improve patient care.

 

NMI, IPMC, and ION

· The company also attended several other relevant UK nutrition conferences: Nutritional Medicine Institute ('NMI') in October, the Integrative & Personalised Medicine Congress ('IPMC') in June and the Institute for Optimum Nutrition ('ION') Open Day.

CNS Builds Business Partner Relationships at Industry Trade Fair

Medica

· In November the Company attended Medica in Germany. The event allowed CNS to meet with existing business partners, whilst also providing the opportunity to connect with potential new partners in currently untapped territories for the Group.

 

Commenting, Jag Grewal, Chief Executive Officer, said:

"Collaboration with global and UK-based key opinion leaders in the nutritional science field is one of CNS's core values and is a fundamental part of our scientific education programme. As a pioneer in personalised health and nutrition it is vital for us to be leading the way with webinars exploring emerging aspects of science related to gut health, and attending key industry events alongside these high-profile speakers.

 

"This engagement is critical in our drive to foster strong partnerships with healthcare practitioners and potential business partners. It leads to better awareness and understanding of the Company, which in turn creates demand for our products, and helps cement the Group as a global thought leader in its field."

 

Contacts: 

Cambridge Nutritional Sciences PLC

www.cnsplc.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Charlotte Edgar

Mob: 07980 541 893 / Mob: 07884 664 686 /

Sam Allen

Mob: 07502 558 258

 

 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRANKDBNABDDFBK
12
Date   Source Headline
22nd Apr 20267:00 amRNSTrading & Business Update
31st Mar 20265:35 pmRNSHolding(s) in Company
31st Mar 20265:32 pmRNSHolding(s) in Company
19th Nov 20257:00 amRNSDirector/PDMR Shareholding
10th Nov 20257:00 amRNSHalf-year Report
4th Nov 20257:00 amRNSNotice of Results & Investor Presentation
25th Sep 20254:30 pmRNSResult of AGM
28th Aug 20257:00 amRNSNotice of AGM & Annual Report
21st Aug 20257:00 amRNSGrant of Options
19th Aug 20257:00 amRNSFinal Results
31st Jul 20257:00 amRNSNotice of Results & Investor Presentation
10th Jul 20257:00 amRNSDirectorate Change
2nd Jul 20257:00 amRNSHolding(s) in Company
27th May 20257:00 amRNSTrading Update
23rd May 20257:00 amRNSResolution on HSE Matter
8th Apr 20257:00 amRNSGrant of Options
1st Apr 20257:00 amRNSAppointment of Chief Executive Officer
21st Mar 202511:33 amRNSHolding(s) in Company
19th Mar 20257:00 amRNSOmega Diagnostics Summons Update
18th Mar 20252:48 pmRNSHolding(s) in Company
6th Feb 20257:00 amRNSDirector/PDMR Shareholding
30th Jan 20259:41 amRNSDirector/PDMR Shareholding
21st Jan 20254:03 pmRNSOmega Diagnostics court summons
16th Jan 20257:00 amRNSSettlement of DHSC Claim
7th Jan 20255:25 pmRNSHolding(s) in Company
7th Jan 20255:20 pmRNSHolding(s) in Company
4th Dec 20241:33 pmRNSHolding(s) in Company
4th Dec 20241:32 pmRNSHolding(s) in Company
21st Nov 20247:00 amRNSHalf-year Report
15th Nov 20249:24 amRNSNotice of Results and Investor Presentation
27th Sep 202411:20 amRNSResult of AGM
15th Aug 20243:44 pmRNSPosting of Annual Report and Notice of AGM
13th Aug 20247:00 amRNSDirectorate Change
5th Aug 202410:29 amRNSGrant of Options
25th Jul 20247:00 amRNSFinal Results
10th Jul 20247:00 amRNSNotice of Results
6th Jun 20244:26 pmRNSGrant of Options
24th May 20247:00 amRNSDirectorate Change
22nd Apr 20248:21 amRNSTrading Update and Directorate Change
3rd Apr 20247:00 amRNSQ2 2024 Industry Events Schedule
30th Jan 202412:50 pmRNSIssue of Equity and Total Voting Rights
29th Jan 20247:00 amRNSAppointment of Operations Director
22nd Jan 20247:00 amRNSScientific Educational Webinar and Industry Event
18th Dec 20233:51 pmRNSHolding(s) in Company
4th Dec 20237:00 amRNSScientific Educational Programme expanded
28th Nov 20233:56 pmRNSHolding(s) in Company
23rd Nov 20237:00 amRNSHalf-year Report
22nd Nov 202310:59 amRNSHolding(s) in Company
20th Nov 202311:09 amRNSHolding(s) in Company
17th Nov 202312:55 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.